| scholarly article | Q13442814 |
| P356 | DOI | 10.4062/BIOMOLTHER.2016.162 |
| P8608 | Fatcat ID | release_7m6mn7iuaffx5e4bymabswtkye |
| P932 | PMC publication ID | 5590792 |
| P698 | PubMed publication ID | 28190319 |
| P2093 | author name string | Qi Liu | |
| Zhiqiang Liu | |||
| Ping Yuan | |||
| Xiangyu Zhou | |||
| P2860 | cites work | Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells | Q37170788 |
| TGF-β1 promotes scar fibroblasts proliferation and transdifferentiation via up-regulating MicroRNA-21 | Q37198600 | ||
| Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase | Q37862942 | ||
| Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management | Q38204330 | ||
| Mechanism of cancer drug resistance and the involvement of noncoding RNAs | Q38204798 | ||
| Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies. | Q42412981 | ||
| Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells | Q43191223 | ||
| Roots of clinical resistance to STI-571 cancer therapy | Q43744914 | ||
| Protein-coding genes and long noncoding RNAs are differentially expressed in dasatinib-treated chronic myeloid leukemia patients with resistance to imatinib | Q46970334 | ||
| microRNA expression profiling as supportive diagnostic and therapy prediction tool in chronic myeloid leukemia. | Q53813904 | ||
| Long noncoding RNAs in human disease: emerging mechanisms and therapeutic strategies | Q86314547 | ||
| A Pituitary-Derived MEG3 Isoform Functions as a Growth Suppressor in Tumor Cells | Q24299283 | ||
| Maternally expressed gene 3 (MEG3) noncoding ribonucleic acid: isoform structure, expression, and functions | Q24623420 | ||
| A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? | Q24629627 | ||
| Structural mechanism for STI-571 inhibition of abelson tyrosine kinase | Q27627097 | ||
| Functionalized graphene oxide mediated adriamycin delivery and miR-21 gene silencing to overcome tumor multidrug resistance in vitro | Q28488394 | ||
| The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell | Q28533535 | ||
| Identification of drug combinations containing imatinib for treatment of BCR-ABL+ leukemias | Q28540799 | ||
| The Long Noncoding RNA MEG3 Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma | Q28547372 | ||
| Non-coding RNAs: regulators of disease | Q29618040 | ||
| MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer | Q29620125 | ||
| First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib | Q33392977 | ||
| Identification of an imprinted gene, Meg3/Gtl2 and its human homologue MEG3, first mapped on mouse distal chromosome 12 and human chromosome 14q. | Q33897694 | ||
| MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes. | Q34142871 | ||
| MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase-kinase 3. | Q35013542 | ||
| Molecular mechanisms of resistance of leukemia to imatinib mesylate | Q35704820 | ||
| BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase | Q36026747 | ||
| Gene silencing by DNA methylation in haematological malignancies | Q36816162 | ||
| A Multi-centric Bioequivalence Trial in Ph+ Chronic Myeloid Leukemia Patients to Assess Bioequivalence and Safety Evaluation of Generic Imatinib Mesylate 400 mg Tablets | Q37097538 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 5 | |
| P921 | main subject | imatinib | Q177094 |
| microRNA | Q310899 | ||
| chronic myeloid leukemia | Q729735 | ||
| P304 | page(s) | 490-496 | |
| P577 | publication date | 2017-02-13 | |
| P1433 | published in | Biomolecules & therapeutics | Q20020559 |
| P1476 | title | LncRNA MEG3 Regulates Imatinib Resistance in Chronic Myeloid Leukemia via Suppressing MicroRNA-21. | |
| P478 | volume | 25 |
| Q94526828 | Aberrant LncRNA Expression in Leukemia |
| Q58800444 | BMP4 Upregulation Is Associated with Acquired Drug Resistance and Fatty Acid Metabolism in EGFR-Mutant Non-Small-Cell Lung Cancer Cells |
| Q58610531 | Disordered Regions of Mixed Lineage Leukemia 4 (MLL4) Protein Are Capable of RNA Binding |
| Q47134555 | LncRNA MEG3 enhances cisplatin sensitivity in non-small cell lung cancer by regulating miR-21-5p/SOX7 axis |
| Q41547616 | LncRNA SNHG5 regulates imatinib resistance in chronic myeloid leukemia via acting as a CeRNA against MiR-205-5p |
| Q49886323 | LncRNA SPRY4-IT was concerned with the poor prognosis and contributed to the progression of thyroid cancer. |
| Q47314991 | Long non-coding RNA MEG3 functions as a competing endogenous RNA to regulate ischemic neuronal death by targeting miR-21/PDCD4 signaling pathway |
| Q59329575 | Long non-coding RNAs in hematological malignancies: translating basic techniques into diagnostic and therapeutic strategies |
| Q47127087 | MALAT1-miR-101-SOX9 feedback loop modulates the chemo-resistance of lung cancer cell to DDP via Wnt signaling pathway |
| Q88637044 | MEG3/miR‑21 axis affects cell mobility by suppressing epithelial‑mesenchymal transition in gastric cancer |
| Q88796944 | MicroRNA21 and the various types of myeloid leukemia |
| Q90274839 | Role of non-coding RNA networks in leukemia progression, metastasis and drug resistance |
| Q58572750 | The SOX2OT/miR-194-5p axis regulates cell proliferation and mobility of gastric cancer through suppressing epithelial-mesenchymal transition |
| Q97072562 | The role of Long Non-Coding RNAs (lncRNAs) and downstream signaling pathways in Leukemia progression |
| Q49623115 | lncRNA FAM83H-AS1 is associated with the prognosis of colorectal carcinoma and promotes cell proliferation by targeting the Notch signaling pathway. |
| Q88424519 | lncRNA MNX1-AS1 Promotes Glioblastoma Progression Through Inhibition of miR-4443 |
Search more.